-
The Lancet, April 2020.
Apr 11, 2020
-
AIDS Research and Infectious Diseases, April 2020 Led by Dr.
Apr 09, 2020
-
PRIOR CASE OF RESISTANCE ON DOLUTEGRAVIR PLUS LAMIVUDINE DUAL THERAPY
AIDS Research and Human Retroviruses, April 2020 The last few years have witnessed increased interest in treating HIV with two instead of three active drugs.
Apr 09, 2020
-
The Journal of Infectious Diseases, March 2020 Direct-acting antivirals (DAAs) targeting hepatitis C virus (HCV) have revolutionized outcomes in HIV coinfection.
Mar 23, 2020
-
The Lancet, March 2020 Dr.
Mar 05, 2020
-
Clinical Infectious Diseases, February 2020 Disturbances in adipose tissue (AT), also known by the general public as “fat,” in people living with HIV include lipodystrophy (fat loss or gain) and obesity.
Feb 28, 2020
-
RISK FACTORS FOR WEIGHT GAIN FOLLOWING SWITCH TO INTEGRASE INHIBITOR–BASED ANTIRETROVIRAL THERAPY
Clinical Infectious Diseases, February 2020 Research suggests that integrase strand transfer inhibitors (INSTIs) are associated with greater weight gain compared to other HIV medications.
Feb 26, 2020
-
Clinical Infectious Diseases, January 2020 Memory problems, difficulty concentrating, and inability to multi-task, among other cognitive issues, are common complaints of people living and aging with HIV.
Jan 03, 2020
-
1077HS/4: PREDICTORS OF VIREMIA IN POSTPARTUM WOMEN ON ANTIRETROVIRAL THERAPY
Journal of Acquired Immune Deficiency Syndrome, January 2020 Undetectable viral load is associated with optimal health outcomes for people living with HIV.
Jan 01, 2020
-
A5260S: FUNGAL MARKER Β-D-GLUCAN INCREASED AFTER ANTIRETROVIRAL THERAPY, ASSOCIATED WITH FAT GAINS
Open Forum Infectious Diseases, November 2019 A5260s was a sub-study of A5257 in which ART-naïve individuals with HIV were randomized to receive atazanavir (ATV)/ritonavir (r), darunavir/r, or raltegravir.
Nov 19, 2019
-
ANTIRETROVIRAL TREATMENT INTERRUPTIONS LOOK DIFFERENT IN POSTPARTUM WOMEN THAN IN MEN
Wolters Kluwer, November 2019 The short-term safety of treatment interruptions (a necessary part of cure studies) is not well-established, particularly in women and racially diverse populations.
Nov 15, 2019
-
A5334S: DIFFERENCES IN DRUG INTERACTIONS BETWEEN THOSE WITH HCV, HIV, AND HIV/HCV COINFECTION
British Journal of Pharmacology, October 2019 One form of treatment for Hepatitis C virus (HCV) is composed of ombitasvir, paritaprevir/ritonavir- plus dasabuvir (OBV/PTV/r + DSV), and weight-based ribavirin.
Oct 27, 2019
